Related Experiment Video

Updated: Jun 11, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

A new insight into hepatitis C vaccine development

Chun I Yu1, Bor-Luen Chiang

  • 1Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.

Journal of Biomedicine & Biotechnology
|July 14, 2010
PubMed

Insights

Hepatitis C virus (HCV) infection is a global health issue with limited treatment options. Research into protective immunity and vaccine development shows promise for future HCV therapies.

Area of Science:

  • Hepatology
  • Immunology
  • Vaccinology

Background:

  • Chronic hepatitis C virus (HCV) infection poses a significant global public health challenge.
  • Current antiviral therapies (pegylated IFN-alpha with ribavirin) exhibit limited efficacy (around 50%) and poor tolerability, especially for HCV genotype 1.
  • No effective vaccine is currently available for HCV prevention.

Purpose of the Study:

  • To discuss viral immune evasion strategies employed by HCV.
  • To identify correlates of protective host immunity against HCV.
  • To review prospective vaccine approaches for chronic HCV infection.

Main Methods:

  • Review of existing literature on HCV immunology and vaccine development.
  • Analysis of viral immune evasion mechanisms.
  • Evaluation of host immune responses (neutralizing antibodies, CD4(+) and CD8(+) T cell responses) associated with HCV clearance.

Main Results:

  • Neutralizing antibodies and robust T cell responses are linked to HCV clearance.
  • Understanding immune correlates provides insights into vaccine design.
  • Various vaccine candidates have been developed and tested pre-clinically.

Conclusions:

  • Identifying protective immunity is crucial for developing an effective HCV vaccine.
  • Further research into immune evasion and host responses will guide future vaccine strategies.
  • Prospective vaccine approaches hold promise for controlling chronic HCV infection.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Human Virome01:26

Human Virome

The human body harbors a vast and diverse viral community known as the human virome. The virome includes bacteriophages that infect bacteria, and eukaryotic viruses that infect human cells. Transient dietary and environmental viruses also contribute to this dynamic ecosystem. Estimates suggest the human body may contain on the order of 10¹³ viral particles, though abundance varies widely by body site and detection method.Comprehensive characterization of the virome has become possible only with...